SCHEMBL6898131

SCHEMBL6898131

CC(=O)SCCN(CCC1CCCCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MME P08473 6/20 0.48
ALDH1A1 P00352 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ACE P12821 4/20 0.45
CPA1 P15085 3/20 0.45
ACE2 Q9BYF1 3/20 0.45
BCHE P06276 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LTA4H P09960 1/20 0.41
POLB P06746 1/20 0.41
EPHX2 P34913 1/20 0.41
CASR P41180 1/20 0.41
LPAR1 Q92633 1/20 0.40
MCHR1 Q99705 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27538229 1.00 MME (0.48) MMEALDH1A1HSD17B10ACECPA1
SCHEMBL27538283 0.89 REN (0.46) ACEBCHETDP1POLBCASR
SCHEMBL27538281 0.89 REN (0.46) ACEBCHETDP1POLBCASR
SCHEMBL6898090 0.87 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4E
SCHEMBL27560011 0.87 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4E
SCHEMBL6898887 0.86 MME (0.53) MMEALDH1A1HSD17B10ACECPA1
SCHEMBL6896981 0.83 LPAR1 (0.50) MMEACECPA1ACE2LMNA
SCHEMBL27538252 0.83 LPAR1 (0.50) MMEACECPA1ACE2LMNA
SCHEMBL27543400 0.81 MME (0.53) MMEACECPA1ACE2LMNA
SCHEMBL6897078 0.81 MME (0.53) MMEACECPA1ACE2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH MME 1516/4885ALDH1A1 1309/4885HSD17B10 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.